Nextcea performs Drug Efficacy & Safety Assessments
using proprietary biomarkers through advanced LC-MS/MS platforms
![](https://nextcea.com/wp-content/uploads/2024/03/LRRK2_sm.png)
LRRK2
Parkinson’s disease
![](https://nextcea.com/wp-content/uploads/2024/03/GBA_sm.png)
GBA
Parkinson’s disease & Gaucher disease
![](https://nextcea.com/wp-content/uploads/2024/03/BTK_sm.png)
BTK
Leukemia / Lymphoma
![](https://nextcea.com/wp-content/uploads/2024/03/Phospholipidosis_sm.png)
Phospholipidosis
Drug-Induced Phospholipidosis / Parkinsonism
Nextcea is dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development.
![](https://nextcea.com/wp-content/uploads/2024/03/Kidney-Safety-Assessment_sm.jpg)
Kidney Safety Assessment
for Oligonucleotide drug candidates